Cruise Ship Injury Case Study: Maritime Law, PI Claim, and Pharmacy Lien

James Wong — Founder & Pharmacist, LienScripts | February 17, 2026 | 9 min read

A cruise passenger fractured her ankle on a wet deck with inadequate safety equipment. After returning home to shore, her health insurer refused injury-related care. A pharmacy lien covered post-return orthopedic medications over 13 months while her maritime personal injury claim against the cruise line worked through federal court — and the pharmaceutical record became a key piece of evidence in the settlement.

Cruise Ship Injury Case Study: Maritime Law, PI Claim, and Pharmacy Lien

Note: This is a fictionalized case study based on composite facts. Names and identifying details are not real. The clinical details represent typical medication patterns for this injury type.

Injuries sustained on cruise ships present some of the most legally unusual personal injury scenarios in the plaintiff bar. The injury occurs at sea, often in international waters. The defendant is a multinational cruise corporation with aggressive in-house legal teams, liability waivers in the ticket contract, and forum selection clauses that may require the case to be filed in a specific federal district far from the plaintiff's home. The law governing the claim — general maritime law — is a specialized body of federal admiralty law that differs significantly from state tort law. And the plaintiff typically returns home before receiving comprehensive medical care, creating a geographical and temporal gap between the injury event and the shore-side treatment record.

This case study examines how a pharmacy lien program filled the treatment and documentation gap for a passenger who sustained a serious ankle fracture on a cruise ship and needed 13 months of post-return pharmaceutical management before her maritime claim resolved.

[!KEY] In cruise ship injury cases, the shore-side treatment record — including pharmacy documentation — is often the only continuous clinical evidence available to the plaintiff, because the ship's medical facility records are controlled by the cruise line and may be incomplete or difficult to obtain.

Case Background

Patient: Renata V. (name changed), 61-year-old female, retired school administrator Incident: Renata was on a 10-day Caribbean cruise. On day 7, while walking along the starboard deck of the ship during moderate seas, she slipped on a wet surface near the pool area. There were no wet-floor warning signs posted. The non-slip deck coating in that area was visibly worn. Renata fell and landed hard on her right ankle and lower leg. On-Ship Medical Treatment: Renata was taken to the ship's medical facility. The on-board physician performed a clinical examination, obtained portable imaging, and diagnosed a trimalleolar ankle fracture — a fracture involving all three malleoli (medial, lateral, and posterior). She was stabilized in a splint, provided with initial pain management, and advised to follow up with an orthopedic surgeon immediately upon returning home. The ship's medical charges were billed directly to Renata at the time of treatment — cruise ship medical facilities are private pay, not covered by standard health insurance. Return and Shore-Side Treatment: Renata returned home four days later (the cruise completed its itinerary). She was seen by an orthopedic foot and ankle surgeon within 48 hours. Given the trimalleolar fracture pattern, surgery was recommended. She underwent open reduction and internal fixation (ORIF) of the ankle within two weeks of returning home. Insurance Situation: Renata had Medicare as her primary coverage and a supplemental policy. Both programs declined to cover injury-related care, citing the coordination-of-benefits language in their policies and directing her to the cruise line's liability coverage as the primary responsible payer. The cruise line's insurer disputed liability and made no voluntary payments during litigation. Attorney: David L. (name changed), an admiralty and maritime plaintiff attorney based in Miami.

The Legal Framework: Maritime Law for Cruise Passengers

It is important to clarify the legal context before examining the medication record, because maritime law shapes everything — including how damages are calculated and what evidence matters most.

Cruise passengers are not seamen. The Jones Act, which provides enhanced remedies for seamen injured in the course of their employment, does not apply to cruise passengers. A passenger injury claim is governed by general maritime law — specifically the duty of a carrier to exercise reasonable care under the circumstances. This is a negligence standard, but one that federal courts have refined significantly through decades of cruise passenger litigation.

Federal maritime jurisdiction. Because Renata's injury occurred on the high seas, her claim was filed in federal court in the Southern District of Florida — the jurisdiction specified in the forum selection clause in her cruise ticket contract. This is almost universal in cruise passenger cases; the major cruise lines are domiciled in Florida, and federal courts in Miami have the largest body of cruise ship injury precedent in the country.

Three-year statute of limitations. Unlike the two-year limit in most state personal injury claims, general maritime law provides a three-year statute of limitations for personal injury. However, cruise ticket contracts typically shorten this to one year for notice and two years for filing. Renata's attorney filed a notice of claim within the contractually required notice period.

The liability theory. David's theory was straightforward: the cruise line was negligent in failing to maintain the non-slip surface in the affected deck area and in failing to post wet-floor warnings during sea conditions that predictably produce wet deck surfaces. The worn non-slip coating was documented in photographs taken at the scene by another passenger.

The Pharmacy Lien: Shore-Side Coverage During Federal Litigation

David enrolled Renata in the LienScripts pharmacy lien program at the time of her orthopedic intake — before the ORIF surgery was performed. Because Medicare and the supplemental policy had declined injury-related coverage, the lien program became her sole pharmaceutical coverage throughout the case.

Medication Timeline

Pre-Operative Phase: Weeks 1-2

Oxycodone/acetaminophen 5/325mg every 6 hours was prescribed for the acute fracture pain in the two weeks prior to surgery. A trimalleolar fracture is one of the more painful ankle injury patterns, and the pre-operative period before ORIF is typically managed with short-term opioids.

Aspirin 81mg daily was added at the direction of the orthopedic surgeon for deep vein thrombosis (DVT) prophylaxis. Ankle fractures with associated immobility carry an elevated DVT risk, and the surgeon's documentation of the DVT prophylaxis rationale was captured in the pharmacy record.

Baclofen 10mg at bedtime for muscle spasm.

Perioperative and Post-Operative Months 1-3

Post-ORIF, the prescription management reflected the complexity of a trimalleolar fracture repair with hardware:

Oxycodone/acetaminophen 5/325mg for the immediate post-surgical period (10-day supply with documented taper plan). The pharmacy record showed the controlled, time-limited nature of the opioid course — the prescription was filled once and not refilled, consistent with appropriate acute post-surgical management.

Enoxaparin 40mg subcutaneous daily for extended DVT prophylaxis — a low-molecular-weight heparin injectable required for 30 days post-operatively given the immobility period. The pharmacy lien covered this as well, documenting an important and often-overlooked element of post-operative orthopedic care.

Celecoxib 200mg daily for ongoing inflammation management as the hardware settled and rehabilitation began.

Gabapentin 300mg three times daily was initiated at month 2 for neuropathic ankle pain — a common sequela after ankle ORIF involving the posterior tibial nerve territory. The surgical field in trimalleolar repairs involves dissection near nerve structures, and post-operative neuropathic pain often requires gabapentinoid management during the nerve recovery period.

[!KEY] Post-ORIF neuropathic ankle pain is frequently underestimated in premises liability ankle fracture cases. Pharmacy documentation of gabapentinoid therapy initiated weeks after surgery — rather than immediately post-operatively — signals a new neuropathic development rather than simple acute pain, strengthening the argument for ongoing nerve damage.

Months 4-13: Long-Term Recovery

By month 4, the surgical wound was healed and Renata had begun formal physical therapy. The pharmaceutical management shifted to address the slower-resolving components:

Gabapentin 600mg three times daily — the dose was increased at month 4 when Renata reported insufficient pain control with the initial dose. The titration was documented with clinical rationale.

Duloxetine 30mg daily, titrated to 60mg at month 6, was added for combined neuropathic ankle pain and the significant depression that had developed during Renata's 13-month recovery. As a retired woman who had been highly active — she had booked the cruise specifically as a post-retirement trip — the extended immobility and permanent hardware in her ankle represented a profound quality-of-life loss. Her primary care physician documented the onset of depressive symptoms directly related to the functional limitation.

Zoledronic acid (single annual infusion) at month 5 — Renata's orthopedist ordered a bone density assessment post-fracture, which revealed osteopenia. The zoledronic acid infusion was prescribed for bone health optimization during the healing period. This is an often-overlooked pharmaceutical component that the lien program covered and documented.

Topical diclofenac sodium 1% gel applied to the ankle twice daily from month 5 onward — for localized inflammatory pain management without systemic NSAID exposure. The topical route was specifically chosen to minimize gastrointestinal and renal risks in a 61-year-old patient on concurrent systemic medications.

By month 10, Renata was walking with a functional gait but continued to experience chronic ankle pain on prolonged standing and on uneven surfaces. Her surgeon documented permanent hardware retention, residual post-traumatic arthritis developing at the ankle joint, and a projected need for ongoing pain management.

Ship's Medical Records: A Controlled Evidentiary Challenge

One practical reality in cruise ship cases is that the on-ship medical records are maintained by the cruise line's medical staff, and obtaining them typically requires formal discovery. David subpoenaed the ship's medical records, which documented the initial diagnosis and stabilization. However, the records were sparse — consistent with the limited resources of a shipboard facility — and were produced by counsel for the cruise line during discovery rather than voluntarily.

The contrast between the sparse on-ship records and the 13-month detailed shore-side pharmacy record was itself instructive. The shore-side record documented the full trajectory of a serious surgical ankle injury with hardware, bone density management, and neuropathic complications. The clinical complexity captured in the pharmacy lien record provided a clinical narrative that the shipboard records alone could never have supplied.

[!KEY] In cruise ship injury cases, the plaintiff controls the shore-side treatment record — including pharmacy documentation — while the defendant controls the ship's medical records. Building a detailed, well-organized shore-side pharmaceutical record is one of the few evidentiary areas where the plaintiff has a structural advantage.

Settlement Outcome

The case settled before trial. David's damages theory included medical bills (including the ship's medical facility charges, which were documented separately), the pharmacy lien balance, future medical costs including projected continued pain management and possible future hardware removal, lost quality-of-life damages, and general maritime law non-economic damages.

The cruise line's counsel had initially characterized the injury as a "common ankle sprain" and disputed the negligence theory. David responded with the photographs of the worn deck surface, a maritime safety expert who opined that the worn non-slip coating fell below the applicable standard of care, and a 13-month pharmaceutical record documenting the full arc of a surgical spinal fracture with hardware — not a sprain. The settlement reflected surgical medical bills, the lien balance, and substantial non-economic damages.

Key Takeaways for Maritime Plaintiff Attorneys

Cruise ship injury cases have a longer litigation runway than standard auto or premises liability cases — federal docket timelines, complex discovery involving international defendants, and the contractual limitations period all extend the duration. A pharmacy lien program is uniquely suited to this environment because it covers medications for as long as the case takes to resolve, with no out-of-pocket pressure on the patient to discontinue treatment.

Build the shore-side record deliberately and continuously from the moment of the patient's return. Enroll in the pharmacy lien at the first orthopedic or treating physician appointment. Document everything. In maritime cases where the defendant controls the on-ship medical records, your client's shore-side treatment record — especially the pharmacy documentation — may be the single most organized and comprehensive clinical evidence in the case.

Related Resources

• Ankle Fracture Surgery: Medications and Pharmacy Lien
• What Is a Pharmacy Lien?
• Pharmacy Lien Statute of Limitations
• Health Insurance Subrogation vs. Pharmacy Lien
• Slip and Fall Injury Medications